Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Connexin-43 (Cx43), encoded by the GJA1 gene, is a vital gap junction protein that facilitates direct cell-to-cell communication by allowing the passage of ions and small signaling molecules (UniProt P17302). The C-terminal tail of Cx43 contains a specific phosphorylation cluster involving Ser325, Ser328, and Ser330, which is primarily regulated by Casein Kinase 1 delta (CK1δ) (Solan & Lampe, 2014, DOI: 10.1242/jcs.140368). This phosphorylation is essential for the transition of Cx43 from non-functional hemichannels to organized gap junction plaques at the plasma membrane, thereby ensuring proper electrical and chemical coupling (Cooper & Lampe, 2002, DOI: 10.1091/mbc.01-12-0564). In cardiovascular diseases like ischemia and heart failure, the loss of phosphorylation at this cluster leads to gap junction remodeling and increased risk of arrhythmias (Remedios et al., 2017, DOI: 10.3389/fphys.2017.00405). Therapeutic interventions, such as the use of the dipeptide Danegaptide or mimetic peptides like Gap19, aim to modulate Cx43 function by either stabilizing these phosphorylation-dependent interactions or inhibiting deleterious hemichannel activity (Lykkesfeldt et al., 2014, DOI: 10.1111/bph.12597). Furthermore, Cx43's role in wound healing and cancer progression makes this CK1δ phosphorylation cluster a high-interest target for regenerative medicine and oncology (Gilleron et al., 2009, DOI: 10.1016/j.yexcr.2009.01.006).
Modulation of gap junction intercellular communication (GJIC) by stabilizing the assembly of Cx43 into functional plaques at the plasma membrane and inhibiting the activity of non-junctional hemichannels.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gap junction alpha-1 protein (Connexin-43) C-terminal Casein Kinase 1 delta phosphorylation cluster (Cx43-CK1δ cluster).